An Exploration of the Protective Effects of Investigators’ Ethical Awareness upon Subjects of Drug Clinical Trials in China
- 68 Downloads
Up till now, China has not enacted any legal mechanisms governing certification or supervision for ethics committees. This article analyses deficiencies in the protection of subjects in clinical drug trials under China’s current laws and regulations; it emphasizes that investigators, as practitioners who have direct contact with subjects, play significant roles in protecting and safeguarding subjects’ rights and interests. The paper compares the status quo in China in this area to that of other countries and discusses ways China might enhance the protection of rights and interests of trial subjects, such as enhancing the ethical awareness of investigators through training, improving laws and regulations, and strengthening the communication between investigators and ethics committees.
KeywordsEthics committees Insurance Informed consent Human subjects research Research ethics China
Compliance with Ethical Standards
Conflict of interest
The authors report no conflicts of interest in this work.
- Afifi, S., N. Maharloui, P. Peymani, et al. 2014. Adverse drug reactions reporting: Pharmacists’ knowledge, attitude and practice in Shiraz, Iran. International Journal of Risk & Safety in Medicine 26(3): 139–145.Google Scholar
- Center for Drug Evaluation. 2014. China drug review annual report, China State Food and Drug Administration. http://www.cde.org.cn/news.do?method=largeInfo&id=313425.
- China State Food and Drug Administration 2003. Good clinical practice of pharmaceutical products. http://www.sda.gov.cn/WS01/CL0053/24473.html
- China State Food and Drug Administration 2014. Good clinical practice of pharmaceutical products, China State Food and Drug Administration (SFDA). http://www.sda.gov.cn/WS01/CL0053/24473.html.
- Cong, Y.L. 2010. Comparative study on the protection of Chinese and American subjects in clinical trial—From the perspective of institutional review board. Journal of Peking University (Health Sciences) 42(6): 625–628.Google Scholar
- International Committee of Medical Journal Editors. 1997. Uniform requirements for manuscripts submitted to biomedical journals. New England Journal of Medicine 1997(336): 309–316.Google Scholar
- Jos, D. 2004. Clinical trial insurance in a comparative law perspective. Medicine & Law 23(2): 211–218.Google Scholar
- Lei, X., W.K. Zheng, H. Wang, et al. 2014. The reasons of poor recording of adverse events in clinical trials and methods for improvement. Chinese Journal of New Drugs 23(11): 1260–1263.Google Scholar
- Le Journal Médical Libanais. 1994. Recommendations guiding physicians in biomedical research involving human subjects. World Medical Association Declaration of Helsinki. 42(2): 2191–2194.Google Scholar
- Levine, R.J. 2001. Lecture on history of human research subject use in the U.S. Medicine & Philosophy 12.Google Scholar
- Li, X., X.X. Li, Z.J. Liu, et al. 2010. Analysis of safety reporting in clinical trials on herbal medicine published in Chinese journals. Chinese Journal of Pharmacovigilance 7(1): 20–24.Google Scholar
- Li, Y.X. and J. Li. 2015. On the significance of communication in the ethical review management of drug clinical trials. Medicine and Philosophy 36 (2A): 33–36.Google Scholar
- Liang, Y.H. 2012. Efficacy observation of treating proteinuria with nephritis rehabilitation film combined with Campbell water capsules. Clinical Journal of Chinese Medicine 4(2): 41–42.Google Scholar
- Nakamura, T., N. Ichikawa, K. Egashira, et al. 2008. Comparison of compensation-related documents provided by clinical trial sponsors and medical institutions. Japanese Journal of Pharmaceutical Health Care & Sciences 34(5): 461–466.Google Scholar
- Shen, Y.H., Z.F Zhang. and Z. Q. Li 2011. Current status and regulatory measures for the ethics committee of drug clinical trial institutions in China. Chinese Journal of Clinical Pharmacology 27(8): 654–656.Google Scholar
- Speers, M. 2012. Accreditation of human research protection programs. In Principles and Practice of Clinical Research, edited by J. Gallin and F. Ognibene, 161–170. Washington D.C.: Association for the Accreditation of Human Research Protection Programs, Inc.Google Scholar
- Wei, Y., M.Z Liang., S.Z. Wu, et al. 2013. The participating willingness of subjects and ethic consideration in clinical study. Chinese Journal of Clinical Research 10(2): 26–29.Google Scholar
- Yao, Z.P., X. Jin, J.W. Wang, et al. 2012. Ethic problems and strategies for drug clinical trials in China. China Pharmacy 23(21): 1931–1933.Google Scholar
- Zeng, L.F., J. Liu, J.K. Pan, et al. 2015. Intentional attitude analysis for adverse drug event reporting of principal investigators in clinical trials. Chinese Journal of New Drugs 24(10): 1150–1154.Google Scholar
- Zhou, Y.Z., Y.P. Zhang, T.T. Guo, et al. 2015. Reporting of informed consent and ethics committee approval in clinical trials of antihypertensive drugs. Chinese Journal of New Drugs 24(10): 1141–1144.Google Scholar